FROM YAHOO NEWS Latest news, live updates on 2024 election results XETRA - Delayed Quote ? EUR Biotest Aktiengesellschaft (BIO3.DE) Follow Compare 27.10 -0.20 (-0.73%) At close: November 5 at 5:36 PM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Biotest AG (WBO:BIO3) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... Biotest AG reports a 35% revenue increase and FDA approval for Yimmugo, setting the stage for U.S. market entry in 2025. GuruFocus.com ? 27 days ago BTTAY Biotest wins FDA approval for plasma protein therapy The US Food and Drug Administration (FDA) approved Biotest’s Yimmugo for the treatment of primary antibody deficiencies. Pharmaceutical Technology ? 4 months ago BTTAY GRFS Performance Overview Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is DAX P Return BIO3.DE DAX P YTD -12.46% +14.95% 1-Year -13.02% +26.78% 3-Year -31.04% +20.13%
